Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/11038
Full metadata record
DC FieldValueLanguage
dc.contributor.authorChing, M S-
dc.contributor.authorMihaly, G W-
dc.contributor.authorAngus, Peter W-
dc.contributor.authorMorgan, Denis J-
dc.contributor.authorDevenish-Meares, S-
dc.contributor.authorYeomans, Neville D-
dc.contributor.authorSmallwood, R A-
dc.date.accessioned2015-05-16T00:37:00Z
dc.date.available2015-05-16T00:37:00Z
dc.date.issued1991-02-01-
dc.identifier.citationBritish Journal of Clinical Pharmacology; 31(2): 166-70en_US
dc.identifier.otherPUBMEDen
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/11038en
dc.description.abstract1. This study investigated the mechanism of the increase in oral bioavailability of omeprazole during repeated oral dosing. Eight patients with duodenal ulcer received an i.v. dose of omeprazole before and after a 4-week course of oral omeprazole, 20 mg daily, given as enteric-coated granules. 2. AUCoral and oral bioavailability (F) increased during omeprazole treatment by 50% (P less than 0.01) and 35% (P less than 0.05), respectively. 3. There was no change in the systemic clearance of omeprazole after i.v. dosage following the course of treatment. 4. We conclude that the increased omeprazole AUC observed on repeated administration of enteric-coated granules is due to increased systemic availability rather than decreased systemic elimination. The increased availability appears to be due to increased gastrointestinal absorption rather than decreased first-pass hepatic extraction.en_US
dc.language.isoenen
dc.subject.otherAdministration, Oralen
dc.subject.otherAdulten
dc.subject.otherAgeden
dc.subject.otherBiological Availabilityen
dc.subject.otherDuodenal Ulcer.drug therapyen
dc.subject.otherFemaleen
dc.subject.otherHalf-Lifeen
dc.subject.otherHumansen
dc.subject.otherInjections, Intravenousen
dc.subject.otherMaleen
dc.subject.otherMiddle Ageden
dc.subject.otherOmeprazole.administration & dosage.pharmacokinetics.therapeutic useen
dc.subject.otherTablets, Enteric-Coateden
dc.titleOral bioavailability of omeprazole before and after chronic therapy in patients with duodenal ulcer.en_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleBritish Journal of Clinical Pharmacologyen_US
dc.identifier.affiliationMedicine (University of Melbourne)en_US
dc.description.pages166-70en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/2049231en
dc.type.contentTexten_US
dc.type.austinJournal Articleen
local.name.researcherAngus, Peter W
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.languageiso639-1en-
item.openairetypeJournal Article-
crisitem.author.deptVictorian Liver Transplant Unit-
crisitem.author.deptGastroenterology and Hepatology-
crisitem.author.deptMedicine (University of Melbourne)-
crisitem.author.deptOffice for Research-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

18
checked on Mar 28, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.